echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Kantai Bio "23-price pneumonia vaccine" exported to Uzbekistan, the old category to tap new markets.

    Kantai Bio "23-price pneumonia vaccine" exported to Uzbekistan, the old category to tap new markets.

    • Last Update: 2020-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Kantai Bio wholly-owned subsidiary Beijing Minhai Biotech Co., Ltd. "23-price pneumococcal polysaccharide vaccine" was issued by Uzbekistan drug registration certificate.
    announced that the current access to Uzbekistan's drug registration certificate, is another milestone in the internationalization of Kantai bio-internationalization, is conducive to improving the visibility and influence of Kantai bio-international market, has a positive impact on the development of Kantai bio-international market, in line with its "going out" development strategy.
    from last year's annual report, exports are not actually the main source of revenue for Kantai Bio.
    2019, Kantai's bio-product exports will account for less than 1% of total revenue, or just 0.03%.
    but in the case of the "23-price pneumococcal polysaccharide vaccine", exports may be a major market strategy to increase revenue.
    "23-price pneumococcal polysaccharide vaccine" is not Kantai bio-original and pioneering category.
    the first domestic "23-price pneumococcal polysaccharide vaccine" is the Chengdu Institute of Biological Products ("Chengdu Institute") production of "Hui Yikang", in 2006 has been approved for listing.
    April 2017, Watson Bio's 23-price pneumococcal polysaccharide vaccine was also approved by the State Food and Drug Administration.
    the vaccine, which is the third of its kind developed in China.
    August 13, 2019, Kantai Bio's "23-price pneumococcal polysaccharide vaccine" was approved and issued by the State Drug Administration.
    only in the domestic market, Kantai Bio is facing competition from a number of enterprises with a first-in-the-nation advantage, especially Chengdu's "23-price pneumococcal polysaccharide vaccine" batch issuance has been outstanding.
    the first half of this year, Chengdu approved more than half of the total, according to statistics released by the Chinese Academy of Sciences.
    and Conte chose to export to Uzbekistan, the competitive pressure is relatively small.
    not only that, but the "23-price pneumococcal polysaccharide vaccine" is not easy to promote in itself.
    vaccine recommends vaccination for young children over 2 years of age who are infirm or have repeated pneumonia and those over 60 years of age, while the highest mortality rate among pneumococcal infections is among children under 2 years of age.
    World Health Organization estimates that 1.6 million people worldwide die each year from pneumococcal infections, 460,000 of them infants and young children.
    about 2 million people in our country are infected with pneumococcal bacteria each year, with the highest infant mortality rate among children under 2 years of age.
    , because of the out-of-the-way vaccine, people over the age of 60 are less willing to vaccinate.
    vaccine also used to prevent pneumococcal disease in China also has a 13-price pneumococcal combination vaccine, such a vaccine market prospects in china or better than the 23-price pneumonia vaccine.
    it belongs to the polysaccharin binding vaccine, stimulate infants and young children to produce antibodies with good results, children under 2 years of age can also produce a good antibody response, and can produce immune memory, strong protection of long-lasting.
    While Kantai Bio chose to export to Uzbekistan, in addition to practicing an international strategy, the scarcity of vaccines against pneumococcal diseases in less economically developed areas may also be one of the reasons, and some remote areas will now use the 23-price pneumonia vaccine as a remedy for unvaccinated 13-price pneumonia vaccine.
    Kantai Bio was founded in 1992, has been engaged in the development, production and sale of human vaccines, in addition to 23-price pneumococcal polysaccharide vaccine, is currently on the market for products such as cell-celled haemophilus influenzae type B vaccine, recombinant hepatitis B vaccine (brewing yeast), haemophilus influenzae type b combined vaccine and measles rubella combined detoxification vaccine, product types cover immunization programmes and non-immunization vaccines.
    Kangtai Biological has more than 30 projects in research, of which 3 have applied for drug registration approval.
    , Kantai Bio "13-price pneumococcal combination vaccine" has applied for drug registration approval, is in the review stage.
    to Snow Source: Euro Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    reproduce content at the same time does not represent the position of this site.
    leave a message here.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.